ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly jardiance (empagliflozin, incl. Glyxambi, Synjardy & Trijardy XR) — Worldwide revenue ($M) ($M)
Form 10-Q / 10-K Note 2 & MD&A
Latest, Q2 2026
1,232
Period ended Jun 30, 2026
Change on a year earlier
+78.6%
690 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Jardiance (empagliflozin, incl. Glyxambi, Synjardy & Trijardy XR) — Worldwide revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,232 | +78.6% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,114 | +9.9% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 769 | -35.9% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2025 | Sep 30, 2025 | 959 | +39.7% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 690 | -10.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,014 | +47.7% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,199 | +50.1% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2024 | Sep 30, 2024 | 686 | -2.1% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 770 | +15.2% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 687 | +18.9% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 798 | +30.4% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2023 | Sep 30, 2023 | 701 | +22.2% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 668 | +45.0% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 578 | +37.7% | Form 10-Q (filed 2024-04-30) ↗ |
| Q4 2022 | Dec 31, 2022 | 612 | +41.8% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2022 | Sep 30, 2022 | 573 | +46.8% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 461 | +29.3% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 419 | +34.4% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2021 | Dec 31, 2021 | 432 | +37.8% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2021 | Sep 30, 2021 | 390 | +25.6% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 357 | +36.1% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 312 | +16.6% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Dec 31, 2020 | 314 | +17.0% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 311 | +29.1% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 262 | +13.0% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 268 | +31.4% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 268 | +38.7% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 241 | +44.2% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 232 | +57.5% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 204 | +34.8% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 193 | +34.9% | Form 10-K (filed 2021-02-17) ↗ |
| Q3 2018 | Sep 30, 2018 | 167 | +31.2% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 147 | +42.6% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 151 | +104.1% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 143 | – | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 127 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 103 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 74 | – | Form 10-Q (filed 2018-04-27) ↗ |
Breakdown
What makes up jardiance (empagliflozin, incl. glyxambi, synjardy & trijardy xr) — worldwide revenue ($m)
Cite this data
StockData. (2026). Eli Lilly Jardiance (empagliflozin, incl. Glyxambi, Synjardy & Trijardy XR) — Worldwide revenue ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_jardiance_ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.